The market seems to be mispricing UnitedHealth Group, with its snapshot price trading significantly above its DCF value and Graham Number. The Forward P/E of 11.53 suggests a more reasonable valuation compared to its current P/E, indicating potential growth. However, the Earnings Yield of 3.48% is modest, and the Altman Z-score of 2.52 raises questions about its financial safety. Despite these concerns, the company maintains a “Buy” consensus rating, reflecting investor confidence in its future prospects.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.